for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Coherus Biosciences Inc

CHRS.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
25.15
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
70.13
Market Cap (MIL)
1,232.17
Forward P/E
11.91
Dividend (Yield %)
--

Next Event

Q4 2019 Coherus BioSciences Inc Earnings Release

Latest Developments

More

KKR Biosimilar Reports 5.6% Stake In Coherus Biosciences As Of Nov. 29

Coherus BioSciences Reports Q3 Earnings Per Share Of $0.63

Coherus BioSciences Acquires Commercial Rights For Leading Lucentis Biosimilar In The United States

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Coherus Biosciences Inc

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

Industry

Biotechnology & Drugs

Contact Info

333 Twin Dolphin Dr Ste 600

+1.650.6493530

https://www.coherus.com/

Executive Leadership

Dennis M. Lanfear

Chairman of the Board, President, Chief Executive Officer

Jean-Frederic Viret

Chief Financial Officer

Vincent R. Anicetti

Chief Operating Officer

Peter K. Watler

Chief Technology Officer

Vladimir Vexler

Chief Scientific Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.0K

2018

0.0K

2019(E)

0.4K
EPS (USD)

2016

-3.040

2017

-4.480

2018

-3.220

2019(E)

1.475
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.31
Price To Book (MRQ)
21.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
317.32
LT Debt To Equity (MRQ)
317.32
Return on Investment (TTM)
-6.63
Return on Equity (TTM)
-5.11

Latest News

Latest News

Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount

Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount.

BRIEF-Coherus Prices Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 5.17 MILLION COMMON SHARES PRICED AT $14.50PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Coherus Announces Proposed Public Offering Of Common Stock

* COHERUS BIOSCIENCES INC SAYS COMMENCED UNDERWRITTEN PUBLIC OFFERING OF $75,000,000 OF SHARES OF ITS COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Coherus BioSciences Re-Submits Biologics License Application For CHS-1701

* COHERUS BIOSCIENCES RE-SUBMITS BIOLOGICS LICENSE APPLICATION FOR CHS-1701 (PEGFILGRASTIM BIOSIMILAR CANDIDATE)

BRIEF-Coherus Biosciences Says U.S. Court Grants Motion To Dismiss Patent Infringement Complaint

* COHERUS BIOSCIENCES-U.S. COURT ADOPTED MAGISTRATE JUDGE BURKE'S REPORT & RECOMMENDATION TO GRANT MOTION OF CO TO DISMISS PATENT INFRINGEMENT COMPLAINT

BRIEF-Coherus BioSciences Reports Q4 Loss Per Share $0.84

* COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million

* COHERUS BIOSCIENCES SAYS HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING Source text : (http://bit.ly/2qqVZLs) Further company coverage:

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

BRIEF-Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder

* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:

BRIEF-‍Temasek Holdings reports 11.32 pct passive stake in Coherus Biosciences

* Temasek Holdings (private) Ltd reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

BRIEF-Coherus secures private placement from Temasek

* Coherus Biosciences Inc - Temasek plans to invest up to $150 million over two tranches

BRIEF-Coherus Biosciences Q2 loss $1.08 per share

* Anticipate resubmitting BLA in U.S. At end of Q4 of 2017 for CHS-1701

BRIEF-Coherus Biosciences says completed restructuring plan to reduce operating costs

* Says commenced and completed, a restructuring plan to reduce operating costs and better align its workforce

BRIEF-Coherus Biosciences says projected filing timing for CHS-1420 biologics license application pushed to first half of 2018

* Coherus Biosciences - determined it is prudent to put into place alternative fill & finish vendor to support co's adalimumab biosimilar candidate chs-1420's bla filing

RPT-UPDATE 3-FDA rejects Coherus's biosimilar for Neulasta, shares plunge

Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients.

BRIEF-Coherus to take nearly 6 months to respond to FDA's requests on Neulasta biosmilar

* Coherus BioSciences Inc says the agency can take up to 6 months to evaluate the requested information

FDA rejects Coherus' biosimilar for Amgen's Neulasta

Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) denied the approval of its biosimilar for Amgen Inc's blockbuster treatment, Neulasta, which fights infections in cancer patients.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up